Biologic therapy with vedolizumab (VDZ), a monoclonal antibody that binds to the α4β7 integrin receptor, preventing lymphocyte trafficking to the intestines, or adalimumab (ADA), a monoclonal antibody that binds and neutralises the inflammatory cytokine, tumour necrosis factor, can lead to histological and endoscopic improvement in patients with ulcerative colitis (UC), but their effects on the cellular and molecular inflammatory microenvironment (IME) remain understudied.
Here, artificial intelligence–powered quantification of IME histology and molecular transcriptomics were used to evaluate biomarkers that could inform patient risk stratification and identify histological correlates of UC activity.
These biologics were compared head-to-head in the VARSITY trial.
UEG Week
Takeda